Liquidia Shares Plunge After Adverse Patent Ruling and Analyst Downgrades
Liquidia (LQDA) shares dropped sharply after a court ruled against its key patent claims and analysts lowered price targets in response.
Key points
- Liquidia (LQDA) stock fell sharply after losing a patent ruling that threatens its pulmonary hypertension drug pipeline
- Multiple analysts downgraded LQDA following the ruling, reducing price targets and flagging commercial risk
- Patent loss significantly lengthens the runway before Liquidia can achieve commercial exclusivity for its lead drug
What’s your take on this? Join the discussion below.
Read the full analysis on market.news
🇺🇸 United States Stocks Biotech Liquidia LQDA biotech patent pulmonary-hypertension FDA